BeOne Medicines (ONC) Raw Materials (2024 - 2026)

BeOne Medicines (ONC) posted quarterly Raw Materials of $274.2 million for Q1 2026, up 16.1% quarter-over-quarter from $236.2 million in Q4 2025.

BeOne Medicines (ONC) Raw Materials (2024 - 2026) Analysis & Trends

BeOne Medicines (ONC) has reported Raw Materials for 3 consecutive years, with $274.2 million the latest figure, recorded in Q1 2026.

In Q1 2026, Raw Materials changed N/A year-over-year to $274.2 million; the TTM figure through Mar 2026 stood at $274.2 million (changed N/A YoY), while the FY2025 annual figure was $236.2 million, up 38.46% from the prior year.
Raw Materials advanced to $274.2 million in Q1 2026 per ONC's latest filing, from $236.2 million in the prior quarter.
Across five years, Raw Materials topped out at $274.2 million in Q1 2026 and bottomed at $170.6 million in Q4 2024.
Historically, Raw Materials has averaged $227.0 million across 3 years, with a median of $236.2 million in 2025.
On a YoY basis, Raw Materials climbed as much as 38.46% in 2025 and fell as far as 38.46% in 2025.
BeOne Medicines' Raw Materials stood at $170.6 million in 2024, then jumped by 38.46% to $236.2 million in 2025, then rose by 16.1% to $274.2 million in 2026.
Business Quant data shows ONC's Raw Materials at $274.2 million in Q1 2026, $236.2 million in Q4 2025, and $170.6 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data